Updated results of a phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer.

被引：1
|
作者：
Han, Boram
Kim, Hyeong Su
Choi, Dae Ro
Shim, Byoung Yong
Lee, Kyung Hee
Kim, Jin Won
Kim, Jung Han
Kim, Jung Hoon
Kim, Ho Young
Song, Hunho
Park, Choong Kee
Moon, Sung Hoon
Kim, Jong Hyeok
Jeon, Jang Yong
Lee, Jung Woo
Zang, Dae Young
机构：
[1] Hallym Univ, Med Ctr, Anyang, South Korea
[2] Hallym Univ, Med Ctr, Coll Med, Seoul, South Korea
[3] Hallym Univ, Chuncheon Sacred Heart Hosp, Chunchon, South Korea
[4] Cathol Univ Kore, St Vincents Hosp, Seoul, South Korea
[5] Yeungnam Univ Hosp, Dept Hemato Oncol, Daegu, South Korea
[6] Seoul Natl Univ Bundang Hosp, Dept Internal Med, Seoul, South Korea
[7] Hallym Univ, Coll Med, Med Ctr, Dept Internal Med, Anyang, South Korea
[8] Hallym Univ, Chuncheon Sacred Heart Hosp, Div Hematol Oncol, Dept Internal Med, Chunchon, South Korea
[9] Hallym Univ, Kang Dong Sacred Heart Hosp, Med Ctr, Seoul, South Korea
[10] Hallym Univ, Med Ctr, Anyang, South Korea
[11] Hallym Univ, Sacred Heart Hosp, Dept Internal Med, Anyang, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15778
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15778
引用
下载
收藏
页数：6
相关论文
共 50 条
  • [1] Updated results of a phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer
    Han, B.
    Kim, H. S.
    Choi, D. R.
    Shim, B. Y.
    Lee, K. H.
    Kim, J. W.
    Kim, J. H.
    Kim, H. Y.
    Song, H.
    Zang, D. Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] A phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer.
    Han, Boram
    Kim, Hyeong Su
    Choi, Dae Ro
    Shim, Byoungyong
    Lee, Kyung Hee
    Kim, Jin Won
    Kim, Jung Han
    Kim, Jung Hoon
    Song, Hunho
    Park, Choong Kee
    Moon, Sung Hoon
    Kim, Jong Hyeok
    Jeon, Jang Yong
    Lee, Jung Woo
    Zang, Dae Young
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [3] A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
    Han, Boram
    Kim, Bum Jun
    Kim, Hyeong Su
    Choi, Dae Ro
    Shim, Byoung Yong
    Lee, Kyung Hee
    Kim, Jin Won
    Kim, Jung Han
    Song, Hunho
    Kim, Jong Hyeok
    Park, Choong Kee
    Lee, Jung Woo
    Kim, Min-Jeong
    Zang, Dae Young
    JOURNAL OF CANCER, 2021, 12 (03): : 912 - 917
  • [4] Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer.
    Ueno, Makoto
    Ohkawa, Shinichi
    Kobayashi, Noritoshi
    Sugimori, Kazuya
    Kawaguchi, Yoshiaki
    Kobayashi, Satoshi
    Taguri, Masataka
    Yamanaka, Takeharu
    Mine, Tetsuya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [5] Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer
    Hunho Song
    Boram Han
    Choong Kee Park
    Jong Hyeok Kim
    Jang Yong Jeon
    In-Gyu Kim
    Hyo Jung Kim
    Joo Young Jung
    Jung Han Kim
    Jung Hye Kwon
    Geundoo Jang
    Ho Young Kim
    Hyeong Su Kim
    Dae Ro Choi
    Dae Young Zang
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 845 - 852
  • [6] Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer
    Song, Hunho
    Han, Boram
    Park, Choong Kee
    Kim, Jong Hyeok
    Jeon, Jang Yong
    Kim, In-Gyu
    Kim, Hyo Jung
    Jung, Joo Young
    Kim, Jung Han
    Kwon, Jung Hye
    Jang, Geundoo
    Kim, Ho Young
    Kim, Hyeong Su
    Choi, Dae Ro
    Zang, Dae Young
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (04) : 845 - 852
  • [7] Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer
    Kentaro Sudo
    Taketo Yamaguchi
    Kazuyoshi Nakamura
    Tadamichi Denda
    Taro Hara
    Takeshi Ishihara
    Osamu Yokosuka
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 249 - 254
  • [8] Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer
    Sudo, Kentaro
    Yamaguchi, Taketo
    Nakamura, Kazuyoshi
    Denda, Tadamichi
    Hara, Taro
    Ishihara, Takeshi
    Yokosuka, Osamu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (02) : 249 - 254
  • [9] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
    Morizane, C.
    Okusaka, T.
    Furuse, J.
    Ishii, H.
    Ueno, H.
    Ikeda, M.
    Najima, M.
    Hirokawa, S.
    Nakachi, K.
    Ogura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 206S - 206S
  • [10] A randomized phase II study of gemcitabine plus S-1 versus gemcitabine alone in patients with unresectable pancreatic cancer.
    Omuro, Y.
    Ikari, T.
    Ishii, H.
    Ozaka, M.
    Suyama, M.
    Matsumura, Y.
    Itoi, T.
    Egawa, N.
    Yano, S.
    Hanada, K.
    Kimura, Y.
    Ukita, T.
    Ishida, Y.
    Tani, M.
    Ohoka, S.
    Hirose, Y.
    Hijioka, S.
    Watanabe, R.
    Ikeda, T.
    Nakajima, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345